Printer Friendly

ZILA TO BEGIN MARKETING ORASCAN IN CANADA

 ZILA TO BEGIN MARKETING ORASCAN IN CANADA
 PHOENIX, Oct. 19 /PRNewswire/ -- Zila, Inc. (NASDAQ: ZILA), today


announced that its subsidiary, Zila Pharmaceuticals, Inc., plans to begin marketing Orascan in Canada early in 1993. Orascan is the first early detection system for oral cancer.
 Zila president Joseph Hines said: "The regulatory issues have been resolved and a letter of intent has been signed with a Canadian firm for production and distribution. We expect to begin delivering Orascan to Canadian dentists and physicians as soon as final agreements are complete and packaging components can be delivered from suppliers."
 No lethal disease is easier to cure than oral cancer detected in its early stages. Yet more than 1,000 Canadians and 8,000 Americans die of the disease each year. Three thousand new cases were identified in Canada last year, and 31,000 in the United States. Treatment costs in the United States are running $665 million yearly. The critical problem is that more than half the time, oral cancer is discovered only after the disease has become malignant.
 Orascan is the first simple, inexpensive, safe and effective screening system to be made available commercially for use by dentists, hygienists or physicians during routine check-ups. "And," added Hines, "Orascan is remarkably accurate."
 Zila has applied to the U.S. Food and Drug Administration for approval to market Orascan in the United States, and the company is pursuing regulatory approvals throughout Europe and elsewhere. Orascan is based on a patent held by the National Institutes of Health, a branch of the U.S. government; Zila, through its research affiliate, holds the exclusive rights to market the technology.
 Zila is headquartered at 5227 North 7th Street, Phoenix, Ariz. 85014.
 -0- 10/19/92
 /NOTE: Orascan is a registered trademark./
 /CONTACT: Joseph Hines of Zila, 602-266-6700/
 (ZILA) CO: Zila, Inc. ST: Arizona IN: MTC SU:


TW -- DC014 -- 1729 10/19/92 15:05 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Oct 19, 1992
Words:318
Previous Article:BALTIMORE GAS & ELECTRIC COMPANY ANNOUNCES MANAGEMENT CHANGE
Next Article:BFGOODRICH DIRECTORS SET QUARTERLY DIVIDEND
Topics:


Related Articles
ZILA, INC. SEEKS FDA MARKETING APPROVAL FOR ORAL LESION DETECTION DEVICE
ZILA, INC., SETS FIRST QUARTER REVENUE RECORDS
INSURANCE COVERAGE FOR ORASCAN TAKES EFFECT IN CANADA
CANADIAN JOURNAL RECOMMENDS DENTISTS USE ZILA'S ORAL CANCER DETECTION SYSTEM TO AVOID MALPRACTICE
FDA ACTS ON ZILA'S ORASCAN(TM); COMPANY READIES DOMESTIC PRODUCTION TO SUPPORT EXPORT SALES
Zila & Bio-Dental Technologies Sign Definitive Agreement For Acquisition
Zila to Trade on Nasdaq National Market
Zila Names Dr. Ralph E. Green to Head OraTest(TM) USA
'The Supply House' to Become 'Zila Dental Supply'
Zila Dental Supply Chosen By National Association of Dental Plans

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters